Novavax, Inc.

Michael J Massare

Gale Smith

Ye Liu

Peter M Pushko

Yingyun Wu

Jing-Hui Tian

Bin Zhou

Sarathi Boddapati

Gregory M Glenn

Erica Shane

Robin A Robinson

Cynthia Oliver

Thomas Kort

Margaret Nathan

Gregory J Glenn

Gale E Smith

Margret Nathan

Louis Fries

Iksung Cho

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.

Modified RSV F proteins and methods of their use

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Vaccine compositions having improved stability and immunogenicity

Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Methods and compositions for treating respiratory disease

Disclosed herein are coronavirus Spike (S) proteins and nanoparticles comprising the same, which are suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Corona virus vaccine formulations

Coronavirus vaccine formulations

Disclosed herein are nanoparticles containing MERS virus proteins in polymer structures, and compositions containing the nanoparticles formulated for administration as immunogenic compositions. Also provided herein are vector constructs encoding the proteins, and host cells containing the vector constructs. The disclosure also includes methods of making the nanoparticles and administering them to vertebrates, including methods of inducing immune responses to MERS that reduce or prevent infection by the virus.

Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods

This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

Highly efficient influenza matrix (M1) proteins

Growing community of inventors

Mt. Airy, MD, United States of America

Michael J Massare